Beam
Emily Brennan has a diverse work experience in the field of biotechnology. Emily started their career at Claritas Genomics as a Molecular Technologist from November 2014 to January 2018. Following that, they joined Editas Medicine as a Research Associate from February 2018 to August 2021. Currently, they are employed at Beam Therapeutics, where they first worked as a Senior Research Associate I from August 2021 to September 2023, and now holds the position of a Principal Research Associate from August 2023 onwards.
Emily Brennan has a Bachelor's degree in Biochemistry from Stony Brook University, obtained from 2010 to 2014. Emily also holds a certification as a Technologist in Molecular Biology from the American Society for Clinical Pathology (ASCP), obtained in August 2017.
Beam
10 followers
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines.